Celltrion Inc. is a South Korean biopharmaceutical business headquartered in Incheon. Celltrion Healthcare is responsible for the global marketing, sales, and distribution of Celltrion's biological therapies. The company's medicines are manufactured in mammalian cell culture facilities that have been designed and built to meet the cGMP criteria of the US FDA and the GMP standards of the European Medicines Agency.

Celltrion of South Korea has recently earned a name for itself with biosimilar copies of big-name bestsellers, and it aims to add even more in the future years. Celltrion is spending big on an ambitious R&D and manufacturing expansion at its existing South Korean headquarters to get there. Celltrion, a significant force in the Korean pharmaceutical business, did the unthinkable by launching the world's first "antibody biosimilar" from a country with a relatively underdeveloped pharmaceutical sector. The company has successfully pioneered various unexplored areas, and it expects to continue its expansion as a global biopharmaceutical company with unique methods to small molecule medications and new companies such as the Ubiquitous-healthcare platform business.

Celltrion is an abbreviation for "cell" in body and "Triones," a guiding star also known as the Big Dipper. The company's name expresses the desire to enhance human health and welfare by being a "guiding star" in the bio industry. Celltrion Healthcare works tirelessly to realize its goal of "rewriting the world's bio-history." It works to make the world a better and healthier place by emphasizing the importance of coexistence and prosperity.

Founded: 1991
Headquarters: Incheon, South Korea
Website: https://www.celltrion.com/

SK Bioscience is a vaccination company founded in 2018 by SK chemicals. It is also one of the largest pharma companies in South Korea. Prior to the spin-off from SK Chemicals in 2008, it had concentrated on premium vaccines as new growth drivers. The corporation continued to invest in its manufacturing and production infrastructure.As a result of these efforts, it launched the first Korean cell culture-based trivalent influenza vaccine in 2015, followed by the world's first cell culture-based quadrivalent influenza vaccine, the world's second shingles vaccine, and Korea's second varicella vaccine.

Through global collaboration with the Bill & Melinda Gates Foundation, CEPI, GSK, and others, SK Bioscience created South Korea's first COVID-19 vaccine, SKYCovione, as well as a universal vaccine to prevent 'Sarbecovirus.' SK Bioscience created the world's first quadrivalent cell-cultured influenza vaccine, SKYCellflu, which received WHO PQ (Pre-qualification) certification in 2019. The company then created SKYZoster, the world's second shingles vaccine, and SkyVaricella, the world's second WHO PQ-certified chickenpox vaccine. SK Bioscience plans to launch a pneumococcal conjugate vaccine, cervical cancer vaccine, typhoid conjugate vaccine, and rotavirus vaccine after growing its R&D pipeline through global alliances with public and private universities.

Based on its technologies, all SK Bioscience employees strive to meet the company's purpose, 'We promote human health, from prevention to cure.' To meet social expectations, SK Bioscience will establish trust as a global creative vaccine and biotech partner, allowing all stakeholders, including employees, customers, shareholders, and local communities, to be proud and pleased.

Founded: 2018
Headquarters: Gyeonggi, South Korea
Website: https://www.skbioscience.com/

SK Biopharmaceuticals is a subsidiary of the SK Group, Korea's second largest corporation. Within the SK Group, it is in charge of developing innovative next-generation drugs. Many innovative drug candidates in the area of CNS have been developed by SK Biopharmaceuticals, led by the clinical development center (SK Life Science) in the United States and the research facility in Pangyo Techno-valley, Gyeonggi-do. The Company primarily develops and manufactures pharmaceuticals, such as epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, and bipolar disorder drugs. The company is also involved in the research of novel drugs.

SK Biopharmaceuticals is the only Korean business to have marketed two FDA-approved novel medications and to have developed cenobamate (an epileptic therapy) from discovery to FDA approval and commercialization. SK Biopharmaceuticals also discovered and licensed out solriamfetol (a therapy for sleep disorders), which received FDA and EMA approval. SK Biopharmaceuticals is expanding its research domain outside epilepsy, based on the gathered research capabilities. SK Biopharmaceuticals opened a research center in 2017 to begin its oncology expansion.

To become a true big biotechnology company, SK Biopharmaceuticals plans to diversify its product offerings beyond the treatment of central nervous system (CNS) disorders with drugs like anti-cancer treatment, cell and gene therapy (CGT), and digital therapeutics, building on successes like the successful commercialization of new drugs.

Founded: 1993
Headquarters: Gyeonggi, South Korea
Website: https://www.skbp.com/

Yuhan would be fourth largest pharma company in South Korea. Yuhan Corporation is a pharmaceutical and chemical firm based in South Korea. Yuhan Corp (Yuhan) develops, manufactures, and sells pharmaceutical products. APIs and intermediates for antibiotics, antivirals, antifungals, anti-thrombotic, anti-inflammatory, anti-diabetic, and antihyperlipidemics are available from the company. The company provides completed goods to treat hypertension, coronary artery disease, hyperlipidemia, cerebral thrombosis, and other disorders. Other pharmaceutical and biopharmaceutical companies can use Yuhan's custom synthesis services. It sells active pharmaceutical ingredients (API) and completed goods both domestically and internationally.

Yuhan has not only achieved one of the highest market caps and sales revenue in the Korean pharmaceutical industry, but has also been named one of the most respected and trusted companies in South Korea for 20 consecutive years, according to the Korean Management Association. Over the past 80 years, the company has succeeded in founding creed of producing the best medicines and contributing to public health through intensive research and development activities and successful collaboration with multinational pharmaceutical companies.

Yuhan has always prioritized research and development as a top corporate objective. The company approaches R&D using innovative, nimble, and translational strategies. Yuhan is able to maintain its overarching commitment to improving quality of life thanks to this three-pronged dynamic. True to the company's founding mission, Yuhan focuses its R&D efforts on developing the types of products that people require the most

Founded: 1926
Headquarters: Seoul, South Korea
Website: http://eng.yuhan.co.kr/

Hanmi Pharm Co., Ltd. is a pharmaceutical firm based in Seoul, South Korea. It has grown to be one of the largest corporations not just in Korea, but also in the region, with over 200 goods sold internationally. Today, Hanmi is also known as Korea's No. 1 R&D investing company, spending more than 10% of its annual revenue on developing next generation Platform Technologies and NCE products.

Antibiotics, antidiarrheal medications, osteoporosis medications, liver supplements, and antiemetics are among the prescription drugs offered by the company. It sells over-the-counter products such as nutritional supplements, calcium supplements, and vitamins. Hanmi Pharmaceuticals' medications are used to treat cancer, depression, dementia, dermatitis, diabetes, inflammation, cardiovascular disorders, epilepsy, hepatitis, osteoarthritis, gastrointestinal diseases, obesity, and osteoporosis, among other conditions. South Korean manufacturing facilities include Hwaseong, Songpa, and Pyeongtaek. It sells its products and APIs in a number of countries around Europe, Asia-Pacific, and the Americas.

Hanmi Pharmaceuticals advances to become a global leader in pharmaceutical development by developing new biologics, chemical entities, and revolutionary new medications. Hanmi's slogan is "creation and challenge," since the company strives to innovate in the home pharmaceutical market. With RFID technology, the company launched a distribution revolution, as well as the nation's first successful US expansion with IMD and R&D collaboration with worldwide companies. Hanmi has demonstrated its superior technology and capacity with FDC (fixed dose combinations) medications all over the world. Merck exports amosartan, a hypertension medication, to 51 countries worldwide. Hanmi also develops and implements numerous FDC medication initiatives with GSK.

Founded: 1973
Headquarters: Seoul , South Korea
Website: https://www.hanmipharm.com/

Sam Chun Dang Pharm. Co., Ltd is a Korean pharmaceutical firm that primarily manufactures prescription medications. Antibiotics used to treat sepsis, respiratory diseases, and other conditions; circulatory disease medicines, including cardiovascular and endocrine medicaments used to treat diabetes, hypertension, angina, and other conditions under the brand names Glilazide and Atenolol; eye inflammation under the brand names Ofus and Toracin; and anti-inflammatories used to relieve postoperative pains under the brand name Barotase and others.

Sam Chun Dang Pharm is a pioneering pharmaceutical company that is always encouraging new product development through modern R&D and GMP facilities. Furthermore, through exporting good medicines and evolving into a worldwide recognized pharmaceutical company, the company is aggressively pioneering foreign market expansion. Through research and development operations, Sam Chun Dang Pharmaceutical will do its best and continuously innovate to create a firm that is trusted, liked by customers, and has worldwide competitiveness to defend humanity's health and future. That's all about the next largest pharma companies Toplist want to mention.

Founded: 1943
Headquarters: Seoul, South Korea
Website: http://www.scd.co.kr/

Medytox Inc (Medytox) is a pharmaceutical firm based in South Korea that develops, manufactures, and markets biopharmaceutical medicines. Botulinum toxin, hyaluronic acid filler, and medical devices are among the products offered by the company. Neuronox, innotox, and coretox are botulinum toxin-type products. Medytox hyaluronic acid filler gives neuramis a boost. Neurakin cream is also available from the manufacturer. The business offers comfortdual, a medical device that uses high-frequency electricity to coagulate tissue. It operates in Taiwan, China, Hong Kong, Japan, and Thailand, with manufacturing factories, research and development centers, and joint venture firms.

Medytox has grown dramatically since the introduction of botulinum toxin type A Meditoxin® in 2006. Medytox has approximately 40% of the Korean market share since 2009 and is likely to grow even more with the addition of new indications. Medytox has a significant market share in the global botulinum industry. With the goal of expanding into the United States and Europe, it intends to exceed 10% of the worldwide market share through the launch of newly developed botulinum toxin products.

Medytox will expand as a biopharmaceutical industry leader in the future by challenging with a desire for the worldwide market. Medytox presently exports products to 60 countries, including Japan and Brazil. In addition, the company is working hard to break into the markets in the United States and Europe in the near future. Based on these findings, Medytox will be recognized as a global leader in biopharmaceuticals.

Founded: 2000
Headquarters: Chungbuk, South Korea
Website: http://www.medytox.com/

GC Biopharma is a South Korean biopharmaceutical business based in Yongin. GC Pharma focuses in the discovery and marketing of oncology and infectious disease vaccines, protein treatments, and therapeutic antibodies. The company is involved in biotherapeutics research, development, manufacture, and sales, including plasma proteins, recombinant antibodies, and vaccines. Green Cross created "Hepavax B," the world's third hepatitis B vaccine, in 1983, "Hantavax," the world's first vaccine against epidemic hemorrhagic fever in 1988, the world's second varicella vaccine in 1995, "Greengene," the world's fourth recombinant antihemophilic drug, and "Hunterase," the world's second Hunter syndrome treatment, in 2012 as well as one of the largest pharma companies in South Korea.

GC Biopharma, a South Korean biotechnology pioneer, is gearing up to take another significant step toward guaranteeing a better and happier future for all people globally. The essential principles that govern GC Biopharma on its journey toward its next goal are challenge and innovation, care and compassion, transparency and honesty, and respect and dedication. Its mission is to usher in a brighter and healthier future for all of humanity. Over the last five decades, GC Biopharma has been involved in a wide range of pharmaceutical research and development.

Pharmaceutical research is fraught with difficulties and difficulties. Recognizing the importance of its mission to those suffering from sickness, GC Biopharma has been relentlessly pursuing its goal of being a global health sector leader. GC Biopharma is now poised to join the ranks of the global health industry as an active participant in the research, development, and delivery of a diverse range of pharmaceutical products, medical devices, and healthcare services for improved global prevention, diagnosis, and treatment of diseases of the body and mind.

Founded: 1967
Headquarters: Gyeonggi, South Korea
Website: http://www.globalgreencross.com/

Daewoong Pharmaceutical Co., Ltd. is a South Korean pharmaceutical firm headquartered in Seoul. It provides prescription medications, non-prescription drugs, healthcare goods, and APIs. The company manufactures tablets, capsules, ointments, injections, liquids, and sprays. It provides cures for bone and joint disorders, cardiovascular diseases, central nervous system diseases, circulatory system, dermatological, gastrointestinal, and respiratory system conditions. It also handles product development and commercialization via in-licensing, co-marketing, and co-promotion. In Asia, the corporation operates in Japan, the United States, Canada, Switzerland, and Germany, in addition to Indonesia, China, Vietnam, Israel, Thailand, and India.

Daewoong Pharmaceutical Co., Ltd., founded in 1945, has the highest prescription medicine sales in Korea and aspires to be a top 50 worldwide healthcare firm by 2010. Daewoong has developed a strong core competency for innovative medication development and created a cooperative culture for working with worldwide partners in addition to its product portfolio, which includes ten blockbuster drugs.

The company's purpose is to provide the most beneficial overall solutions with drugs and services that contribute to the improvement of valued consumers' quality of life. Daewoong Pharmaceutical will develop its global business with international branches and global partners in the future to become a global healthcare group that contributes to enhancing the quality of life for people all over the world.

Founded: 1945
Headquarters: Seoul, South Korea
Website: https://www.daewoong.co.kr/

LegoChem Biosciences will end the list the largest pharma companies in South Korea. LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company based in South Korea dedicated to the discovery, development, and commercialization of innovative medicines by leveraging chemistry expertise to make conventional biologics more targeted and potent for the benefit of patients with diseases with high unmet medical needs. It is developing long-term pipelines in antibiotics, anticoagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).

The Global Team of Scientific Excellence at the organization is a highly experienced executive team with more than forty years of industry experience in medication discovery, development, and commercialization. The Best ADC Technology Award was given to a proprietary ADC technology with a demonstrated track record of global license to industry leading medicines. Its key strength is medicinal chemistry (Legochemistry), which uses fragment-based drug discovery to generate drug-like compounds faster.

The objective of LegoChem Biosciences Inc is to become a Global Top ADC firm by 2030, establishing LCB's own clinical stage pipeline, revolutionizing the platform to span the whole ADC spectrum, and becoming a pioneer with ADCs beyond traditional cancer therapy. LegoChem Biosciences is now Korea's leading company in ADC therapies, which are designed to destroy tumor cells while leaving healthy cells alone. Its ADC technology was recently recognized at an international ADC conference.

Founded: 2006
Headquarters: Daejeon, South Korea
Website: https://www.legochembio.com/